Colorectal Liver Metastases
Conditions
Keywords
Colorectal Liver Metastases, initially unresectable, ivonescimab, objective response rate
Brief summary
The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab. The main questions it aims to answer are: Does ivonescimab plus chemotherapy raise the objective response rate? What medical problems do participants have when receiving ivonescimab plus chemotherapy? Participants will: Receive ivonescimab and chemotherapy every 3 weeks, no more than 8 cycles. Visit the clinic once every 2 cycles (6 weeks) for checkups and tests. Receive curative surgery, maintenance therapy, or discontinue study treatment according to the expert team's evaluation.
Interventions
DRUGIvonescimab plus chemotherapy
Ivonescimab, 20mg/kg, D1, Q3W; Oxaliplatin, 130mg/m2, D1, Q3W; Capecitabine, 1000mg/m2, BID, D1-D14, Q3W
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years. 2. Histologically confirmed colorectal adenocarcinoma. 3. Radiologically confirmed liver-only metastases. Patients with ≤1 cm extrahepatic lesions not confirmed as metastatic are eligible. 4. No prior systemic therapy or local therapy for metastatic lesions, or completion of neoadjuvant/adjuvant chemotherapy ≥6 months before diagnosed disease recurrence. 5. Liver metastases considered unresectable or borderline resectable by multidisciplinary evaluation. 6. Liver metastases were measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 7. Eastern Cooperative Oncology Group performance status 0-1 8. Life expectancy ≥12 weeks. 9. No contraindications to hepatic resection/ablation, and primary tumor resectable or previously resected. 10. Adequate organ function as determined by normal bone marrow function (hemoglobin ≥80 g/L, absolute neutrophil count ≥1.5×10⁹/L, and platelets ≥100×10⁹/L), renal function (serum creatinine ≤1.5×upper limit of normal \[ULN\] and creatinine clearance ≥30 mL/min), liver function (serum bilirubin ≤2×ULN and serum transaminases ≤5×ULN).
Exclusion criteria
1. Definite extrahepatic metastases. 2. dMMR or MSI-H colorectal cancer. 3. Intolerance to the study drug during prior neoadjuvant/adjuvant therapy. 4. Toxicities from prior therapy have not resolved to ≤ Grade 1 (according to NCI-CTCAE v5.0), except for alopecia (any grade) and peripheral neuropathy (≤ Grade 2). 5. History of or concurrent other malignancies within the past 5 years, except cured localized tumors. 6. Surgery performed within 28 days prior to enrollment. 7. Hypertension with systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg despite antihypertensive treatment. 8. Major cardiovascular events within 12 months prior to enrollment. 9. History of severe bleeding tendency or coagulation disorders; tumor encasement of major blood vessels or significant necrosis or cavitation, and the investigator deems participation in the study may pose a bleeding risk. 10. Active autoimmune disease requiring systemic treatment within the past 2 years. 11. History of immunodeficiency, positive HIV antibody test, or long-term use of corticosteroids or other immunosuppressants. 12. Prior history of allogeneic bone marrow or organ transplantation. 13. Received live vaccines within 30 days prior to the first dose or plans to receive live vaccines during the study period. 14. Allergy to any component of the study drugs; history of severe hypersensitivity reactions to other monoclonal antibodies. 15. Women who are pregnant or breastfeeding. 16. Severe comorbidities or any other condition that precludes safe administration of the study treatment, including but not limited to symptomatic congestive heart failure (Class II or higher per NYHA classification), unstable angina, acute myocardial ischemia, poorly controlled arrhythmias, decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or psychiatric/social conditions that may limit compliance with study requirements or impair the subject's ability to provide written informed consent. 17. Any other condition deemed by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate | At the end of Cycle 8 (each cycle is 21 days) |
| Treatment-Emergent Adverse Events | From the date of enrollment until 90 days after the Cycle 8 (each cycle is 21 days) |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival | From date of enrollment until the date of death, assessed up to 2 years |
| Recurrence-free survival | From the date of curative resection until the date of first documented progression, assessed up to 2 years |
| No evidence of disease rate | 6 months |
| Treatment-related adverse events | From the date of enrollment until 90 days after the Cycle 8 (each cycle is 21 days) |
| Immunotherapy-related adverse events | From the date of enrollment until 180 days after the Cycle 8 (each cycle is 21 days) |
| Disease control rate | At the end of Cycle 8 (each cycle is 21 days) |
| Progression-free survival | From date of enrollment until the date of first documented progression, assessed up to 2 years |
Countries
China
Contacts
Primary ContactLin Yang
Outcome results
None listed